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Background: Medication adherence is associated with improved health outcomes in multiple 
chronic diseases. Information is needed on the effectiveness of specific adherence interventions. 
This study’s objectives were to quantify effects of a targeted mailing intervention on adherence 
among older adults at risk for nonadherence, and to examine associations of individual and plan 
characteristics with adherence.
Materials and methods: Among adults enrolled in a Medicare Advantage Plan with prescrip-
tion drug coverage from May 2014 to June 2015, those identified as eligible for the mailing 
intervention had a late refill for oral antidiabetic medication, statin, angiotensin-converting 
enzyme inhibitor, or angiotensin receptor blocker medication and were previously unreachable 
by telephone. Pharmacy claims data were analyzed with the outcome of 6-month proportion 
of days covered (PDC) before and after the mailing. The t-test and chi-square analyses were 
used to evaluate univariate associations. Multivariable linear and logistic regression models 
were conducted to assess relative covariate effects. A sub-analysis of those with at least one 
medication fill post-mailing was also performed.
Results: A total of 460 non-adherent individuals aged 70±10.5 years, with 50.2% female and 
66.7% white individuals, were included. Of those who were mailed a letter, 24.1% became 
adherent to the specified maintenance medication. Those who received 30-day supplies were 
more than twice as likely to become adherent after the mailed letter than those who received 
30-day supplies or less (P0.05). Baseline higher PDC was also associated with greater 
adherence post-mailing (P0.01). A total of 284 (61.7%) individuals filled their medication 
at least once after the mailed letter; of those, 39.1% became adherent (mean [SD] change in 
PDC =0.15 [±0.28]).
Conclusion: Our findings suggest that a single mailed letter improved medication adherence 
by 24.1% in adults with chronic conditions. As a health plan seeking to improve its customers’ 
well-being and outcomes, Cigna continues to utilize targeted mail interventions to improve 
medication adherence.
Keywords: patient compliance, chronic disease, managed care programs, Medicare, Medicare 
Part D, Medicare Part C, mail distributions, population health, program evaluation
Introduction
Medication adherence has been associated with improved health outcomes in multiple 
chronic disease states, including reduced health care utilization and mortality.1–3 Despite 
the increased medication costs incurred by adherence, larger savings are realized 
through decreased hospital inpatient and emergency department use;4 all-cause medical 
costs have been shown to be lower in adherent patients with diabetes, hypertension, 
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and hypercholesterolemia.5 Improving medication adherence 
to diabetes medication(s) alone could provide a $4.7 billion 
annual cost savings.6 The positive effects and importance of 
medication adherence are especially emphasized in popula-
tions of older adults.
Medicare is the federally-funded United States insurance 
program for adults aged 65 years. The Centers for Medi-
care and Medicaid Services (CMS) incorporates medication 
adherence into their Star Ratings.7 These ratings are used 
to standardize and compare prevention, satisfaction, and 
treatment metrics in order to evaluate and compare health 
plan performance nationally (http://healthinsuranceratings.
ncqa.org). Adherence measures that comprise the ratings 
include oral antidiabetic medication(s), statin medication, 
and angiotensin-converting enzyme inhibitor (ACEI) or 
angiotensin receptor blocker (ARB) medication. While the 
importance of medication adherence has been increasingly 
promoted, recent studies show that medication nonadherence 
remains a significant problem and can be as high as 49.1% 
in those with chronic conditions.8
In their 2018 study, Easthall et al identified patient-
level barriers to adherence in prevention of cardiovascular 
disease and mapped these factors to a conceptual frame-
work designed to create tailored behavioral change.9 Health 
plans with an interest in prevention have taken on the role 
of partnering with individuals to promote healthy behav-
iors through behavioral health benefits like telephonic 
coaching, and helping to better manage disease through 
pharmacy benefits management programs. In-person 
patient counseling has been shown to increase adherence, 
lower blood hemoglobin A1c levels in patients with dia-
betes, and lower low-density lipoprotein cholesterol in 
coronary artery disease patients.10,11 One literature review 
concluded that while pharmacy interventions can improve 
medication adherence, when the intervention stops, so 
do the effects on adherence.12 Health plans are well posi-
tioned to influence medication adherence, and to manage 
prevention and treatment at the system, provider, and 
individual levels.
Identifying system-level modifiable factors associ-
ated with medication adherence may allow more effective 
interventions to be developed in the future. In a US veteran 
population, Watanabe et al observed that new users of statin 
without a copayment were more adherent than their coun-
terparts with a copayment.13 Those utilizing home delivery 
have been shown to have higher adherence rates than those 
utilizing retail pharmacies.14 Managed care organizations, 
such as Medicare Advantage, primarily utilize telephonic 
and mail interventions to reach their participants. While some 
studies have shown that pharmacy telephonic interventions 
have greater improvement in adherence than mail interven-
tions,15,16 a randomized controlled trial found no difference 
in adherence to osteoporosis medication when comparing a 
telephone-based counseling intervention to a control group 
in a Medicare population.17 While mailed letters to physi-
cians along with plan members have been shown to increase 
medication adherence,18,19 the intervention of letters mailed 
only to plan members has not been assessed. It is clear from 
past research that to be effective, such programs should not 
rely on one mode of communication (eg, phone-only), and 
take a “multimodal” contact approach consisting of more 
than one means of outreach (eg, e-mail, mail, and phone) to 
improve adherence.20
The goal of this study was to quantify the impact on adher-
ence of mailed letters, among a targeted Medicare Advantage 
population at risk for nonadherence and unreachable by 
phone. Eligible individuals were identified if they were late 
to refill their chronic disease management medications. If 
they could not be contacted by telephone, a letter specify-
ing the medication that needed to be refilled was mailed to 
the address on file. Evaluating the effectiveness of these 
mailed letters on improving the proportion of days covered 
(PDC) rate and examining both modifiable and static factors 
influencing adherence may allow future interventions to be 
more effective in targeting at-risk individuals and improving 
overall PDC rates in the Medicare population.
Materials and methods
study design and selection
The study protocol was reviewed and approved by the 
University of Houston Institutional Review Board. A retro-
spective pre–post study was performed on adults enrolled in 
a Medicare Advantage Plan with prescription drug coverage 
from May 2014 to June 2015. Individuals must have been 
continuously enrolled in the health plan throughout the 
measurement period, and eligible to receive an adherence-
focused letter via mail within November and December 
2014 as part of the Medicare Advantage Plan’s adherence 
program. Mailing eligibility criteria included having received 
(per pharmacy claims) a prescription for a statin medication, 
ACEI or ARB medication, or oral antidiabetic medication in 
the year 2014, and having been late picking up their refill. 
The letters were mailed if the individual did not answer a 
phone call from a pharmacy representative within three phone 
call attempts or was otherwise unreachable by phone. The 
letters contained individually tailored information including 
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name, medication name (or names compiled through mail 
merge if they were behind on more than one medication), 
last date medication was filled, name and phone number of 
the pharmacy from which they last picked up the medication, 
a general statement of the importance of taking prescribed 
medication and adhering to prescriber recommendations, and 
the health plan regional Medical Director name and contact 
number for questions.
An initial total of 541 individuals were eligible for pre-
screening, in which phase letters were not sent if there had 
not been at least two fills of the specified medication in the 
year 2014 (n=14), or if the individual was adherent to the 
specified medication, defined as PDC 0.8, before the letter 
was sent (n=67). In total, 460 letters were sent. Selection 
criteria are illustrated in Figure 1.
study variables and outcome measures
Letters were written in the preferred language designated 
by the recipient (English or Spanish). Demographic char-
acteristics were included to ensure representativeness and 
generalizability of the findings, account for possible con-
founding, and assist targeting future interventions; these 
factors included age, gender, self-reported ethnicity, and low 
income subsidy eligibility, which were obtained from the 
customer benefits database. Region was classified as West 
Texas (areas Northwest, Southwest, and West of the Houston 
metropolitan area), East Texas (areas Northeast, Southeast, 
East, and including the Houston metropolitan area), or Not 
in Texas, based on residence zip code.
Medication characteristics were obtained from the phar-
macy benefits management database. The specified medica-
tions in the letters were identified via National Drug Code 
numbers. Medication category was denoted as statin, ACEI 
or ARB, or oral antidiabetic. Brand or generic was denoted 
based on the medication name specified in the sent letter. 
Day supply, copay, the pharmacy at which the medication 
was filled at, and the fill history of the specified medication 
was also obtained. The day supply, copay, and pharmacy 
information were identified based on a claim for the specified 
medication’s fill just prior to the letter being sent. Copay was 
defined as the out-of-pocket expense to the customer for the 
medication. Pharmacy type was classified as either retail or 
mail-order pharmacy.
Outcomes were also obtained and calculated from the 
pharmacy benefits management database. PDC was chosen 
as the outcome measure for its documented correlation with 
other adherence measures.21,22 A threshold of PDC 0.8 is 
commonly used to denote dichotomous adherence in extant 
studies,1,23–25 and is used in the Medicare Star Ratings bench-
marking program to compare health plans and providers. 
Initial PDC rate was calculated from pharmacy claims data 
6 months prior to the date the letter was sent. Final PDC was 
calculated from pharmacy claims data 6 months after the date 
the letter was sent. Change in PDC was calculated as the dif-
ference between initial and final PDC. The primary outcome 
of adherence was defined as a final PDC 0.8. Individuals 
were considered to have filled their medication after the 
letter was sent if there was at least one pharmacy claim for 
Medicare Advantage program participants with prescription drug
coverage from May 2014 to June 2015 who had received a
prescription for a statin medication, ACEI or ARB medication, or oral
antidiabetic medication in the year 2014, and were late picking up
their refill (N=514)
Excluded
Analytic sample Mailing eligible (n=460, 89%)
At least one fill of medication after
letter was sent (n=284, 62%)Sub-analysis
• Less than two fills of specified
 medication in previous year
 (n=14, 3%)
• Proportion of days covered >0.8
 (n=67, 13%)
Included
Figure 1 Customer selection flowchart.
Abbreviations: Acei, angiotensin-converting enzyme inhibitor; ArB, angiotensin receptor blocker.
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the specified medication in the 6 months after the letter was 
sent. Days before the next fill of the specified medication 
were calculated based on the date the letter was sent and the 
pharmacy claims data.
statistical analysis
Chi-square proportion tests and Student’s t-tests were 
conducted to describe univariate relationships between 
adherence and individual and medication characteristics. 
A Fisher’s exact test was used to compare proportions 
of the population with PDC 0.8 before and after the 
mailing. A sub-analysis of 284 individuals who filled the 
specified medication at least once after the letter was sent 
was performed to analyze those who did not likely discon-
tinue the medication class or switch to another medication 
within-class.
Two regression models were built to evaluate patient 
characteristics associated with better adherence among 
the patients who received the letters, as adherence is 
best measured using more than one outcome variable. 
A multiple linear regression analysis was conducted with 
an outcome of change in PDC (Table 1). Independent 
variables included medication type and individual charac-
teristics. A multiple logistic regression analysis with the 
same independent variables was also carried out with an 
adherence outcome defined as a final PDC 0.8 (Table 2). 
The days’ supply variable was dichotomous (30 or fewer 
days’ supply vs 30 days’ supply) for both the linear and 
logistic regression models. Multiple regression was also 
used to analyze the subset of 284 individuals who filled 
the specified medication at least once after the mailed letter 
was analyzed (Tables S1 and S2). All statistical analyses 
were performed utilizing SAS Version 9.3 (SAS Institute 
Inc., Cary, NC, USA).
Results
Table 3 shows that while 40% (140/349) of the non-adherent 
participants had medication supply of 30 days or fewer, only 
30 (27%) of the 111 adherent participants had supply of 
30 days or less. Initial PDC was also higher among adherent vs 
non-adherent participants (mean =0.54 vs 0.51, P=0.013).
Of the 460 non-adherent participants who were mailed 
letters, 111 (24.1%) became adherent after the mailed letter 
(Fisher’s exact test 0.001) and the mean (± SD) change 
in PDC was −0.10 (±0.40). The mean (SD) age of the par-
ticipants was 69.98 (±10.48) years, with 50.2% female and 
66.7% self-reported as white race individuals. Univariate 
chi-square and Student’s t-test comparisons among categories 
Table 1 linear regression analysis of change in 6-month PDc 
before vs after the mailed letter
Beta (standard error) P-value
language of letter −0.050 (0.048) 0.299
Age −0.004 (0.002) 0.041
gender −0.044 (0.037) 0.238
ethnicity −0.019 (0.023) 0.410
region 0.027 (0.029) 0.342
low income subsidy eligibility 0.024 (0.040) 0.553
Medication category 0.010 (0.026) 0.693
generic vs brand 0.033 (0.086) 0.701
Day supply 0.123 (0.039) 0.002
copay −0.002 (0.002) 0.180
Pharmacy type 0.020 (0.121) 0.872
Abbreviation: PDc, proportion of days covered.
Table 2 Logistic regression analysis of adherence defined as 
6-month PDc of at least 80% after the mailed letter
OR (95% CI) P-value
language of letter
english reference reference
spanish 0.739 (0.383–1.426) 0.368
Age
 Age, years 0.994 (0.972–1.016) 0.594
gender
Female reference reference
Male 0.968 (0.615–1.524) 0.888
ethnicity
White reference reference
hispanic 0.673 (0.323–1.402) 0.291
African-American 1.008 (0.538–1.888) 0.981
Asian 1.049 (0.185–5.937) 0.957
region of Texas
Out of Texas reference reference
West 1.359 (0.338–5.471) 0.666
east 1.563 (0.401–6.091) 0.520
low income subsidy eligibility
no reference reference
Yes 1.189 (0.725–1.951) 0.492
Medication category
statin reference reference
Acei/ArB 0.649 (0.396–1.061) 0.085
Oral antidiabetic 0.777 (0.406–1.489) 0.447
generic vs brand
generic reference reference
Brand 0.773 (0.262–2.281) 0.641
Day supply
30 days or less reference reference
30 days 2.198 (1.307–3.696) 0.003
copay
copay, $ 0.994 (0.973–1.016) 0.587
Pharmacy type
retail reference reference
Mail order 1.028 (0.254–4.159) 0.969
initial PDc
PDc 39.283 (2.764–558.363) 0.007
Abbreviations: Acei, angiotensin-converting enzyme inhibitor; ArB, angiotensin 
receptor blocker; PDc, proportion of days covered.
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for the outcome of adherence are reported in Table 3. The 
medications specified in the letter were primarily for generics 
(93.7%) and were comprised of statins (42.6%), ACEIs or 
ARBs (41.1%), and oral antidiabetic medications (16.3%). 
Those who filled more than 30 days of medication at a time 
were more likely to become adherent after the mailed letter 
than those who filled a 30-day supply or less (chi-square 
P=0.013). Also, the mean (SD) initial PDC was 0.51 (±0.11) 
and there was a significant difference in initial PDC between 
those who became adherent after the mailed letter and those 
who did not (Student’s t-test, P=0.013).
A total of 284 (61.7%) participants filled the specified 
medication at least once after the mailed letter. Adherence 
data for this subset along with the overall cohort are reported 
in Table 4. Of this subset, 39.1% became adherent after the 
letter was mailed and the mean (SD) change in PDC was 
0.15 (±0.28). There was a mean (SD) of 39.01 (±42.58) days 
before the next fill after the date the letter was mailed.
The multiple linear regression results for the outcome of 
change in PDC are presented in Table 1 for the whole cohort. 
Days’ supply was found to be significantly associated with 
change in PDC (β standard error [SE] =0.12 (0.04), P=0.002). 
Also, age was significantly associated with a small decrease 
in PDC (β [SE] =−0.004 [0.002], P=0.041). Medication 
category was not significantly associated with change in 
PDC in this model.
Table 3 Baseline Medicare Advantage Plan participant and medication characteristicsa
n (%) Not adherent  
at final, n (%)
Adherent at  
final, n (%)
P-value
language of letter 0.216b
english 362 (78.7) 270 (74.6) 92 (25.4)
spanish 98 (21.3) 79 (80.6) 19 (19.4)
Age 0.676c
Age, years 70.0±10.5 70.1±10.7 69.6±9.9
gender 0.784b
Female 231 (50.2) 174 (75.3) 57 (24.7)
Male 229 (49.8) 175 (76.4) 54 (23.6)
ethnicity 0.602b
White 307 (66.7) 232 (75.6) 75 (24.4)
hispanic 66 (14.4) 54 (81.8) 12 (18.2)
African-American 80 (17.4) 58 (72.5) 22 (27.5)
Asian 7 (1.5) 5 (71.4) 2 (28.6)
region 0.576b
Out of Texas 16 (3.5) 13 (81.3) 3 (18.8)
West Texas 221 (48.1) 171 (77.4) 50 (22.6)
east Texas 223 (48.5) 165 (74.0) 58 (26.0)
low income subsidy eligibility 0.575b
no 222 (48.3) 171 (77.0) 51 (23.0)
Yes 238 (51.7) 178 (74.8) 60 (25.2)
Medication category 0.223b
statin 196 (42.6) 141 (71.9) 55 (28.1)
Acei/ArB 189 (41.1) 150 (79.4) 39 (20.6)
Oral antidiabetic 75 (16.3) 58 (77.3) 17 (22.7)
generic vs brand 0.655b
generic 431 (93.7) 326 (75.6) 105 (24.4)
Brand 29 (6.3) 23 (79.3) 6 (20.7)
Day supply 0.013b
30 days or less 170 (37.0) 140 (82.4) 30 (17.7)
30 days 290 (63.0) 209 (72.1) 81 (27.9)
copay 0.782c
copay, $ 4.36±12.64 4.45±13.41 4.07±9.89
Pharmacy type 0.805b
retail 449 (97.6) 341 (76.0) 108 (24.1)
Mail order 11 (2.4) 8 (72.7) 3 (27.3)
initial PDc 0.013c
PDc 0.51±0.11 0.51±0.12 0.54±0.09
Notes: aValues represent mean ± sD for age, copay, and initial PDc. bchi-squared test. ct-Test.
Abbreviations: Acei, angiotensin-converting enzyme inhibitor; ArB, angiotensin receptor blocker; PDc, proportion of days covered.
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The multiple logistic regression results for the outcome 
of adherence after the mailed letter with a C-statistic of 
0.63 are displayed in Table 2 for the entire cohort. Those 
who filled a 30-day supply of medication at a time had 
increased adherence after the mailed letter, compared to 
those who filled less than a 30-day supply (OR =2.2; 95% 
CI =1.3–3.7; P=0.003). Initial PDC was also significantly 
associated with becoming adherent after the mailed letter 
(OR =39.3; 95% CI =2.8–558.4; P=0.007). Neither age nor 
medication type (statin medications vs ACEIs or ARBs) was 
significantly associated with adherence improvements in the 
multivariable model.
Tables S1 and S2 report multiple regression analyses 
of the subset who filled the specified medication at least 
once after the mailed letter. Initial PDC was not assessed 
in these analyses. Days’ supply was found to be associ-
ated positively with change in PDC within this model 
(β [SE] =0.14 [0.034]; P0.001). Also, in the subset, Texas 
vs out-of-state geographic region was associated with change 
in PDC (β [SE] =0.045 [0.022]; P=0.045). The multiple 
logistic regression results for the outcome of adherence had 
a C-statistic of 0.745. Days’ supply 30 days at baseline was 
associated with greater adherence compared to those with a 
30-day supply or less (OR =2.743; 95% CI =1.514–4.970; 
P=0.001). There was a significant difference in initial PDC 
between those who became adherent after the mailed letter 
and those who did not (OR =39.283; 95% CI =2.764–558.363; 
P=0.007). Region and generic medications were not identified 
as significant predictors of adherence in this model.
Discussion
The present study demonstrated a 24.1% increase in adher-
ence following a pharmacy intervention of a single mailed 
letter sent to a population of older individuals previously 
non-adherent to statins, ACEI/ARBs, or oral antidiabetic 
medications, and who were previously unreachable by 
telephone.
While our data did not corroborate past research suggest-
ing higher adherence to ACEI compared to other medication 
classes,26,27 the overall increase of 24.1% among these specific 
medications targeting chronic disease prevention (statins, 
ACE inhibitors/ARBs, and oral antidiabetic medications) 
was associated with PDC at baseline, and with days’ supply. 
The mailing strategy and medications studied appear well-
targeted for effectiveness in chronic diseases given past 
research showing that mailed letters increased adherence to 
antidepressant medication by only 2% compared to controls.18 
Our data also corroborate past research on the added value of 
multiple modes of contact at the patient, provider, and system 
levels; Jing et al describe that mailed letters to physicians 
can lower nonadherence rates from 35.6% to 30.8%, with 
a decrease to 27.7% when patients are also mailed letters.19 
Managed care organizations should consider a strategy of 
tailored mailings to try to reach all of their non-adherent 
customers in an effort to improve patient health outcomes 
and improve plan quality ratings.
Individuals who filled more than 30 days of medica-
tion at a time were more likely to become adherent after 
the mailed letter than those who filled a 30-day supply or 
less. Also, higher initial PDC was a significant predictor of 
becoming adherent after the mailed letter. These findings are 
consistent with past studies’ findings of higher adherence 
rates with 90- vs 30-day supply.28,29 There is evidence that 
automatic refill programs can be properly managed in chronic 
disease maintenance to avoid oversupply with both 30- and 
90-day prescriptions, and that such programs are suitable 
for patients who have memory or transportation barriers to 
refilling medications at regular pharmacies.30 To improve 
Table 4 PDc rates and adherence dataa
Total sample Participants with one or more medication fill after the letter 
was sent
Total letters (n) 460 Total letters (n) 284
initial PDc (mean ± sD) 0.51±0.11 initial PDc (mean ± sD) 0.52±0.11
Final PDc (mean ± sD) 0.41±0.39 Final PDc (mean ± sD) 0.67±0.28
change in PDc (mean ± sD) −0.10±0.40 change in PDc (mean ± sD) 0.15±0.28
Adherent at final, n (%)
no
Yes
349 (75.9)
111 (24.1)
Adherent at final, n (%)
no
Yes
60.9 (173)
39.1 (111)
Filled after letter, % (n)
no
Yes
38.5 (176)
61.7 (284)
Days before next fill
39.01
42.58
Note: aValues represent mean ± SD for initial PDC, final PDC, change in PDC, and days before next fill.
Abbreviation: PDc, proportion of days covered.
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medication adherence, Medicare Advantage Plans should 
encourage their customers and prescribers to use 90- rather 
than 30-day supplies of chronic medications.
limitations and strengths
More than one-third of those who received a mailed letter 
(38.5%) did not fill the specified medication within 6 months. 
It is a limitation of the present study that the claims data did 
not allow exclusions due to provider-instructed medication 
discontinuation or switching. Determining such cases and 
excluding them before mailing letters would reduce the 
denominator and improve effectiveness as measured by 
PDC, also helping target the intervention further to applicable 
prescribing patterns.
Valid and reliable adherence measurement using claims 
data has always posed a challenge in research. Use of PDC 
as an outcome measure carries certain limitations, including 
the possibility that a prescription could be filled according 
to schedule but not taken as prescribed. Medication event 
monitoring systems such as pill bottle caps or daily logs 
were designed to overcome this challenge, but a potential 
measurement bias where medications were being filled and 
“stockpiled” rather than taken would apply to customers 
using mail-order pharmacies,14 only 11 individuals (less 
than 2% of the analytic sample in the present study) used 
home delivery or mail-order pharmacies. While our data 
demonstrated a higher adherence rate in those using home 
delivery or mail-order pharmacies (27% adherent after the 
letter) vs those using retail pharmacies (24% adherent after 
the letter), these counts were too small to evaluate statistical 
significance.
Age was significantly associated with the outcome of 
change in continuous PDC in the linear regression, but not 
for dichotomous PDC in the logistic regression. In this study, 
individuals previously non-adherent to statin medications 
showed greater responsiveness to the mailing than those 
previously non-adherent to ACEIs or ARBs. Conversely, 
one study demonstrated oral antidiabetic medication as 
being a significant predictor of adherence compared to ARBs 
and statins.27 Future research should continue to evaluate 
the relative effects of disease-specific factors among these 
chronic conditions.
There was no statistically significant medication adher-
ence differences according to measured categories of eth-
nicity, copay, or pharmacy type, despite having previous 
literature support the association between these characteris-
tics and medication adherence. While minorities have been 
shown to have lower adherence in some studies,31,32 in this 
analysis there was no detectable difference by race. Our data 
did not corroborate previous research from 2014 conclud-
ing an effect of copayment on adherence,13 but this could be 
due to the fact that the previous study was conducted in an 
exclusively veteran population.
One assumption in the present study was that each 
individual who was mailed a letter also received and read 
the letter. However, the address listed in the organization’s 
system may have been incorrect, the letter may never have 
been opened, or there could have been language or literacy 
barriers. Also, this study analyzed only pharmacy prescrip-
tion claims viewed by the Medicare Advantage Plan. If a 
person had multiple insurance providers or paid cash for some 
of their prescriptions, this would not have been captured in 
the analysis.
This study also assumed that each individual being 
prescribed these medications should be taking them every 
day, while some indications may utilize alternative dos-
ing. However, this inaccuracy would be consistent across 
multiple time points and is also present in the CMS Part 
D Stars Ratings (the national federal agency plan quality 
rating system). To address the possibility that individuals 
may have discontinued or switched medication throughout 
the year, a sub-analysis of those who filled the medication 
at least once after the mailed letter was performed. As 
shown in Table 4 as well as Tables S1 and S2, the results 
were robust to varying this assumption. Another limitation 
of this study was its pre–post design, which led to limited 
causal inference.33 However, claims data investigations that 
require continuous enrollment to be included in the analytic 
sample are important in planning and allocating resources 
for improving quality of care and designing prospective 
randomized studies.
In quantifying improvements in adherence among Medi-
care Advantage participants using PDC and pharmacy claims 
data, this study maximized health plan data resources and 
population health analytics to identify a mailing intervention 
for further use and investigation.
Conclusion
A single mailed letter significantly improved medication 
adherence by 24.1% in a non-adherent population that could 
not be reached previously by telephone. To our knowledge, 
this is the first study to analyze the targeted intervention con-
comitantly with multiple individual-, plan-, and system-level 
characteristics associated with improved medication adher-
ence in chronic diseases. Future studies should incorporate 
a control group, and track associated health outcomes as 
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a measure of intervention effectiveness. As a health plan 
seeking to improve its customers’ well-being and outcomes, 
teams within Cigna are continuing to utilize targeted mailing 
interventions to help improve medication adherence.
Acknowledgments
This work was funded by Cigna. Some of these results have 
been submitted for presentation as a peer-reviewed poster at 
the American Managed Care & Specialty Pharmacy Annual 
Meeting in April 2016. The abstract was awarded a bronze 
medal and appears in the conference proceedings.
Author contributions
Esse, Abughosh, Serna, and Mann contributed to the study 
design. Mann collected the data. Abughosh, Esse, Castel, 
and Mann performed the data interpretation. Mann wrote 
the manuscript, and all authors contributed to data analysis, 
drafting and revising the article, gave final approval of the 
version to be published, and agree to be accountable for all 
aspects of the work.
Disclosure
At the time the work was conducted, Mann, Esse, Castel, 
and Serna were all full-time employees of Cigna Corpora-
tion or its operating subsidiaries. The authors report no other 
conflicts of interest in this work.
References
1. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonad-
herence on hospitalization and mortality among patients with diabetes 
mellitus. Arch Intern Med. 2006;166(17):1836–1841.
2. Wu JR, Frazier SK, Rayens MK, Lennie TA, Chung ML, Moser DK. 
Medication adherence, social support, and event-free survival in patients 
with heart failure. Health Psychol. 2013;32(6):637–646.
3. Zhao Y, Zabriski S, Bertram C. Associations between statin adherence 
level, health care costs, and utilization. J Manag Care Spec Pharm. 2014; 
20(7):703–713.
4. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medica-
tion adherence leads to lower health care use and costs despite increased 
drug spending. Health Aff. 2011;30(1):91–99.
5. Sokol MC, Mcguigan KA, Verbrugge RR, Epstein RS. Impact of medi-
cation adherence on hospitalization risk and healthcare cost. Med Care. 
2005;43(6):521–530.
6. Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence 
to diabetes drugs is linked to less hospital use and could save nearly 
$5 billion annually. Health Aff. 2012;31(8):1836–1846.
7. Centers for Medicare & Medicaid Services, Center for Medicare. Medi-
care 2015 Part C & D Star Rating Technical Notes; 2015;1–118. Avail-
able from: https://www.cms.gov/medicare/prescription-drug-coverage/
prescriptiondrugcovgenin/performancedata.html. Accessed January 3, 
2016.
8. Halava H, Korhonen MJ, Huupponen R, et al. Lifestyle factors as predic-
tors of nonadherence to statin therapy among patients with and without 
cardiovascular comorbidities. CMAJ. 2014;186(12):E449–E456.
 9. Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence 
in patients prescribed medicines for the prevention of cardiovascular 
disease: a conceptual framework. Int J Pharm Pract. 2018.
 10. Brennan TA, Dollear TJ, Hu M, et al. An integrated pharmacy-based 
program improved medication prescription and adherence rates in 
diabetes patients. Health Aff. 2012;31(1):120–129.
 11. Spence MM, Makarem AF, Reyes SL, et al. Evaluation of an outpatient 
pharmacy clinical services program on adherence and clinical outcomes 
among patients with diabetes and/or coronary artery disease. J Manag 
Care Spec Pharm. 2014;20(10):1036–1045.
 12. Davis EM, Packard KA, Jackevicius CA. The pharmacist role in pre-
dicting and improving medication adherence in heart failure patients. 
J Manag Care Spec Pharm. 2014;20(7):741–755.
 13. Watanabe JH, Kazerooni R, Bounthavong M. Association of copay-
ment with likelihood and level of adherence in new users of statins: 
a retrospective cohort study. J Manag Care Pharm. 2014;20(1): 
43–50.
 14. Iyengar RN, Balagere DS, Henderson RR, Lefrancois AL, Rabbitt RM, 
Frazee SG. Association between dispensing channel and medication 
adherence among medicare beneficiaries taking medications to treat 
diabetes, high blood pressure, or high blood cholesterol. J Manag Care 
Spec Pharm. 2014;20(8):851–861.
 15. Márquez Contreras E, Vegazo García O, Martel Claros N, et al. Efficacy 
of telephone and mail intervention in patient compliance with antihy-
pertensive drugs in hypertension. ETECUM-HTA study. Blood Press. 
2005;14(3):151–158.
 16. Walker EA, Shmukler C, Ullman R, Blanco E, Scollan-Koliopoulus M, 
Cohen HW. Results of a successful telephonic intervention to improve 
diabetes control in urban adults: a randomized trial. Diabetes Care. 
2011;34(1):2–7.
 17. Solomon DH, Iversen MD, Avorn J, et al. Osteoporosis telephonic 
intervention to improve medication regimen adherence: a large, prag-
matic, randomized controlled trial. Arch Intern Med. 2012;172(6): 
477–483.
 18. Hoffman L, Enders J, Luo J, Segal R, Pippins J, Kimberlin C. Impact 
of an antidepressant management program on medication adherence. 
Am J Manag Care. 2003;9(1):70–80.
 19. Jing S, Naliboff A, Kaufman MB, Choy M. Descriptive analysis of 
mail interventions with physicians and patients to improve adherence 
with antihypertensive and antidiabetic medications in a mixed-model 
managed care organization of commercial and Medicare members. 
J Manag Care Pharm. 2011;17(5):355–366.
 20. Block G, Azar KM, Romanelli RJ, et al. Diabetes prevention and 
weight loss with a fully automated behavioral intervention by email, 
web, and mobile phone: a randomized controlled trial among persons 
with prediabetes. J Med Internet Res. 2015;17(10):e240.
 21. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adher-
ence to multiple related medications. Am J Manag Care. 2009;15(7): 
457–464.
 22. Steiner JF, Prochazka AV. The assessment of refill compliance 
using pharmacy records: methods, validity, and applications. J Clin 
Epidemiol. 1997;50(1):105–116.
 23. Choudhry NK, Glynn RJ, Avorn J. Untangling the relationship 
between medication adherence and post-myocardial infarction out-
comes: medication adherence and clinical outcomes. Am Heart J. 
2014;16758(1):51e55.
 24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 
353(5):487–497.
 25. Schmittdiel JA, Nichols GA, Dyer W, Steiner JF, Karter AJ, Raebel MA. 
Health care system-level factors associated with performance on Medi-
care STAR adherence metrics in a large, integrated delivery system. 
Med Care. 2015;53(4):1–337.
 26. Viana M, Laszczynska O, Mendes S, et al. Medication adherence to 
specific drug classes in chronic heart failure. J Manag Care Spec Pharm. 
2014;20(10):1018–1026.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
2.
38
.1
69
.2
50
 o
n 
11
-O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2019:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
45
Targeted mailing interventions to improve medication adherence
 27. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and 
persistence across 6 chronic medication classes. J Manag Care Pharm. 
 2009;15(9):728–740.
 28. Leslie RS, Gilmer T, Natarajan L, Hovell M. A multichannel medica-
tion adherence intervention influences patient and prescriber behavior. 
J Manag Care Spec Pharm. 2016;22(5):526–538.
 29. Taitel M, Fensterheim L, Kirkham H, Sekula R, Duncan I, Supply 
Medication Days’. Medication days’ supply, adherence, wastage, and 
cost among chronic patients in Medicaid. Medicare Medicaid Res Rev. 
2012;2(3).
 30. Matlin OS, Kymes SM, Averbukh A, et al. Community pharmacy auto-
matic refill program improves adherence to maintenance therapy and 
reduces wasted medication. Am J Manag Care. 2015;21(11):785–791.
 31. Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/
Ethnic and gender gaps in the use of and adherence to evidence-based 
preventive therapies among elderly Medicare Part D beneficiaries after 
acute myocardial infarction. Circulation. 2014;129(7):754–763.
 32. Zhang Y, Baik SH. Race/Ethnicity, disability, and medication adherence 
among medicare beneficiaries with heart failure. J Gen Intern Med. 
2014;29(4):602–607.
 33. Campbell DS J. Experimental and quasi-experimental designs for 
research. Chicago, IL: Rand-McNally; 1963.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
2.
38
.1
69
.2
50
 o
n 
11
-O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2019:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
46
Mann et al
Supplementary materials
Table S1 Sub-analysis of letter recipients with medication filled 
after letter was sent (n=284)
Linear regression analysis of change in PDC – change in 
6-month PDC from before the mailed letter to after the 
mailed letter
Beta (standard error) P-value
language of letter −0.009 (0.044) 0.834
Age −0.001 (0.002) 0.478
gender −0.001 (0.033) 0.980
ethnicity −0.030 (0.021) 0.153
region: Texas vs out of state 0.045 (0.022) 0.045
low income subsidy eligibility 0.043 (0.037) 0.251
Medication category −0.007 (0.022) 0.755
generic vs brand −0.060 (0.077) 0.436
Day supply 0.144 (0.034) 0.001
copay −0.001 (0.003) 0.802
Pharmacy type 0.032 (0.104) 0.762
Abbreviation: PDc, proportion of days covered.
Table S2 Sub-analysis of letter recipients with medication filled 
after letter was sent (n=284)
Logistic regression analysis of adherence as measured by 
6-month PDC of at least 80% after the mailed letter
OR (95% CI) P-value
language of letter
english reference reference
spanish 0.948 (0.418–2.148) 0.898
Age
Age, years 1.001 (0.975–1.028) 0.939
gender
Female reference reference
Male 1.045 (0.604–1.811) 0.874
ethnicity
White reference reference
hispanic 0.642 (0.266–1.553) 0.326
African-American 0.743 (0.344–1.603) 0.449
Asian – 0.987
region of Texas
Out of Texas reference reference
West 0.524 (0.088–3.142) 0.480
east 0.912 (0.181–4.603) 0.911
low income subsidy eligibility
no reference reference
Yes 1.667 (0.888–3.130) 0.112
Medication category
statin reference reference
Acei/ArB 0.777 (0.425–1.422) 0.413
Oral antidiabetic 0.743 (0.341–1.619) 0.455
generic vs brand
generic reference reference
Brand 0.305 (0.081–1.147) 0.079
Day supply
30 days or less reference reference
30 days 2.743 (1.514–4.970) 0.001
copay
copay, $ 1.021 (0.981–1.064) 0.303
Pharmacy type
retail reference reference
Mail order 0.845 (0.154–4.649) 0.847
Abbreviations: Acei, angiotensin-converting enzyme inhibitor; ArB, angiotensin 
receptor blocker; PDc, proportion of days covered.
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